Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Doubling down on apoptosis

Human Genome Sciences Inc. doubled its pro-apoptotic play in the cancer space last week as it began a Phase II trial of its lead TRAIL receptor antibody and licensed rights to an inhibitor of apoptosis protein (IAP) antagonist program from Aegera Therapeutics Inc. The partners said the two programs have shown synergistic

Read the full 523 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE